Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

616 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.
De Luca S, Passera R, Fiori C, Bollito E, Cappia S, Mario Scarpa R, Sottile A, Franco Randone D, Porpiglia F. De Luca S, et al. Urol Oncol. 2015 Oct;33(10):424.e17-23. doi: 10.1016/j.urolonc.2015.05.032. Epub 2015 Jul 7. Urol Oncol. 2015. PMID: 26162485
In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
Porpiglia F, Cantiello F, De Luca S, Manfredi M, Veltri A, Russo F, Sottile A, Damiano R. Porpiglia F, et al. Among authors: de luca s. BJU Int. 2016 Oct;118(4):527-34. doi: 10.1111/bju.13318. Epub 2015 Oct 12. BJU Int. 2016. PMID: 26350955 Free article.
High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy.
De Luca S, Passera R, Cattaneo G, Manfredi M, Mele F, Fiori C, Bollito E, Cirillo S, Porpiglia F. De Luca S, et al. BJU Int. 2016 Nov;118(5):723-730. doi: 10.1111/bju.13504. Epub 2016 May 24. BJU Int. 2016. PMID: 27112799
Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.
Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A, Cirillo S, Regge D, Faletti R, Passera R, Fiori C, De Luca S. Porpiglia F, et al. Among authors: de luca s. Eur Urol. 2017 Aug;72(2):282-288. doi: 10.1016/j.eururo.2016.08.041. Epub 2016 Aug 27. Eur Urol. 2017. PMID: 27574821 Free article. Clinical Trial.
616 results